| - |
Alemtuzumab |
Lemtrada® |
For adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features |
NCPE Assessment Process Complete |
25th June 2014 |
 |
| - |
Dabigatran |
Pradaxa® |
For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. |
NCPE Assessment Process Complete |
13th June 2014 |
|
| - |
Dabrafeib |
Tafinlar® |
For the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation. |
NCPE Assessment Process Complete |
24th June 2014 |
|
| - |
Empagliflozin |
Jardiance® |
Add-on combination therapy: In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. |
Rapid review complete |
17th June 2014 |
|
| - |
Omalizumab |
Xolair® |
As an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment. |
Rapid Review Complete |
25th June 2014 |
|
| - |
Teriflunomide |
Aubagio® |
For the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS). |
Assessment process complete |
19th June 2014 |
|
